drugset / Trial / NCT05177822
Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure
Phase 2
Active not recruiting
84 enrolled
Virginia Commonwealth University
National Institute on Aging (NIA) · collabUniversity of Virginia · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
Patients who have a heart attack are at high risk for future development of heart failure ('weakening of the heart'). The researchers believe that the reaction of the heart muscle to injury (inflammation) during a heart attack may be contributing to the risk of heart failure. The current study will test the ability of an anti-inflammatory medicine (anakinra) to block the inflammation in the body during and after a heart attack.
Timeline
- Start
- 2022-05-24
- Primary completion
- 2027-02-22
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anakinra | Protein / enzyme biologic | 100 mg | Subcutaneous |